ArticleAmerican journal of nephrology2012
Mortality associated with dose response of erythropoiesis-stimulating agents in hemodialysis versus peritoneal dialysis patients.
Article in American journal of nephrology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 3 syntheses or guidelines pooled it, 47 citations in OpenAlex.
- Comparative iron management in hemodialysis and peritoneal dialysis patients: a systematic review.Frontiers in nephrology · 2024Pooled it
- Pooled it
- Effect of peritoneal dialysis versus hemodialysis on renal anemia in renal in end-stage disease patients: a meta-analysis.Renal failure · 2017Pooled it
- Erythropoiesis-stimulating agent resistance and mortality in hemodialysis and peritoneal dialysis patients.BMC nephrology · 2013Trial
- Erythropoietin resistance among pediatric patients on chronic hemodialysis: A cross-sectional study.Pediatric nephrology (Berlin, Germany) · 2025Article
- Associations between iron markers with hemoglobin and outcomes in peritoneal dialysis patients: results from the PDTAP study.Clinical kidney journal · 2025Article
- Renal anemia and hyporesponsiveness to ESA for preservation of residual kidney function in patients undergoing peritoneal dialysis.Scientific reports · 2025Article
- Randomized Study on the Efficacy of Standard Versus Low Roxadustat Dose for Anemia in Patients on Peritoneal Dialysis.Kidney international reports · 2022Article
- Effects of Expanded Hemodialysis with Medium Cut-Off Membranes on Maintenance Hemodialysis Patients: A Review.Membranes · 2022Review
- Residual renal function in chronic dialysis is not associated with reduced erythropoietin-stimulating agent dose requirements: a cross-sectional study.BMC nephrology · 2017Article
- The Current State of Peritoneal Dialysis.Journal of the American Society of Nephrology : JASN · 2016Review
- First year survival of patients on maintenance dialysis treatment in Poland.Nagoya journal of medical science · 2015Article
- Association of plasma F2-isoprostanes and isofurans concentrations with erythropoiesis-stimulating agent resistance in maintenance hemodialysis patients.BMC nephrology · 2015Article
- American Society of Nephrology Quiz and Questionnaire 2014: RRT.Clinical journal of the American Society of Nephrology : CJASN · 2015Article
- Association of Erythropoietin-Stimulating Agent Responsiveness with Mortality in Hemodialysis and Peritoneal Dialysis Patients.PloS one · 2015Observational
- The changing landscape of home dialysis in the United States.Current opinion in nephrology and hypertension · 2014Review
- Determinants of hemoglobin variability in stable peritoneal dialysis patients.International urology and nephrology · 2014Observational
- Delta-He: a novel marker of inflammation predicting mortality and ESA response in peritoneal dialysis patients.Clinical kidney journal · 2014Article
- Association of pre-transplant blood pressure with post-transplant outcomes.Clinical transplantation · 2014Article
- Evaluating the benefits of home-based peritoneal dialysis.International journal of nephrology and renovascular disease · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 6 institutions in 2 countries.
Funding
Abstract
backgroundSeveral studies have shown an association between erythropoietin-stimulating agent (ESA) responsiveness and mortality in chronic kidney disease (CKD) patients. In our present study, we examined the association between prescribed ESA dose and mortality in peritoneal dialysis (PD) and hemodialysis (HD) patients. We hypothesized that PD patients received lower ESA dose for the same achieved hemoglobin compared to HD patients and that ESA dose-mortality associations were different between PD and HD patients.
methodsWe compared the prescribed doses of ESA between 139,103 HD and 10,527 PD patients treated in DaVita dialysis clinics from 7/2001 through 6/2006 using adjusted Poisson regression and examined mortality-predictability of prescribed ESA dose and ESA responsiveness index (ESA/hemoglobin) in PD and HD with follow-up through 6/2007 using Cox regression models.
resultsPoisson adjusted ratio of ESA dose of HD to PD was 3.6 (95% CI 3.5-3.7). In PD patients, adjusted all-cause death hazard ratios (HR) for ESA doses of 3,000-5,999, 6,000-8,999 and ≥9,000 U/week (reference <3,000 U/week) were 0.97 (0.87-1.07), 0.85 (0.76-0.95) and 1.08 (0.98-1.18), respectively; whereas in HD patients across commensurate ESA dose increments of 10,000-19,999, 20,000-29,999 and ≥30,000 U/week (reference <10,000 U/week) were 1.14 (1.11-1.17), 1.54 (1.50-1.58) and 2.15 (2.10-2.21), respectively. In PD and HD patients, the adjusted death HR of the 4th to 1st quartile of ESA responsiveness index were 1.14 (1.04-1.26) and 2.37 (2.31-2.43), respectively.
conclusionsBetween 2001 and 2006, most PD patients received substantially lower ESA dose for same achieved hemoglobin levels, and low ESA responsiveness was associated with higher mortality in both HD and PD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.